系统性硬化症中靶向端粒相关蛋白的自身抗体
该研究在约翰霍普金斯和UCSF硬皮病中心的系统性硬化症(SSc)患者血清中筛查靶向端粒酶和shelterin蛋白的自身抗体,发现TERF1自身抗体存在于9.0%(40/442)的SSc患者中,与严重肺病(OR 2.4,p=0.04)和短淋巴细胞端粒长度相关,且在特发性肺纤维化(IPF)患者中亦可见(7.2%),提示端粒功能障碍可能在SSc和肺纤维化发病中具有独特作用。
要点
- TERF1自身抗体在SSc患者中阳性率为9.0%(40/442),与严重肺病相关(OR 2.4,p=0.04)。
- TERF1自身抗体阳性的SSc患者常表现为短淋巴细胞或白细胞端粒长度。
- TERF1自身抗体在IPF患者中阳性率为7.2%(11/152),而在RA、肌炎和健康对照中罕见。
核心结论
- 靶向端粒相关蛋白的自身抗体存在于部分SSc患者中,与短淋巴细胞端粒长度和肺病相关。
- 这些自身抗体对SSc和IPF的特异性提示端粒功能障碍可能在SSc和肺纤维化发病中具有独特作用。
研究设计与样本
- 研究筛查了约翰霍普金斯和UCSF硬皮病中心的SSc患者血清,使用免疫沉淀和ELISA检测靶向端粒酶和shelterin蛋白的自身抗体。
- 采用qPCR、流式细胞术和Flow-FISH测量外周白细胞端粒长度,并探索自身抗体的临床关联。
主要发现
- TERF1自身抗体存在于40/442(9.0%)的SSc患者中,并与严重肺病相关(OR 2.4,p=0.04,Fisher精确检验)。
- 约翰霍普金斯队列中6/6(100%)TERF1自身抗体阳性患者和UCSF队列中14/18(78%)患者分别具有短淋巴细胞或白细胞端粒长度(相对于年龄预期)。
- TERF1自身抗体存在于11/152(7.2%)的IPF患者中,而在类风湿关节炎、肌炎和健康对照中罕见。
关键数值与推荐
- TERF1自身抗体在SSc中阳性率为9.0%(40/442),与严重肺病OR 2.4(p=0.04)。
- TERF1自身抗体阳性患者中短端粒比例:霍普金斯队列6/6(100%),UCSF队列14/18(78%)。
- TERF1自身抗体在IPF中阳性率为7.2%(11/152)。
临床怎么用
- 对SSc患者检测TERF1自身抗体可能有助于识别严重肺病和端粒缩短亚型。
- TERF1自身抗体在IPF中的出现提示端粒功能障碍参与肺纤维化,需在临床中关注肺病评估。
局限性
- 研究未报告样本量以外的具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is an autoimmune fibrotic disease affecting multiple tissues including the lung. A subset of patients with SSc with lung disease exhibit short telomeres in circulating lymphocytes, but the mechanisms underlying this observation are unclear. METHODS: Sera from the Johns Hopkins and University of California, San Francisco (UCSF) Scleroderma Centers were screened for autoantibodies targeting telomerase and the shelterin proteins using immunoprecipitation and ELISA. We determined the relationship between autoantibodies targeting the shelterin protein TERF1 and telomere length in peripheral leucocytes measured by qPCR and flow cytometry and fluorescent in situ hybridisation (Flow-FISH). We also explored clinical associations of these autoantibodies. RESULTS: In a subset of patients with SSc, we identified autoantibodies targeting telomerase and the shelterin proteins that were rarely present in rheumatoid arthritis, myositis and healthy controls. TERF1 autoantibodies were present in 40/442 (9.0%) patients with SSc and were associated with severe lung disease (OR 2.4, p=0.04, Fisher's exact test) and short lymphocyte telomere length. 6/6 (100%) patients with TERF1 autoantibodies in the Hopkins cohort and 14/18 (78%) patients in the UCSF cohort had a shorter telomere length in lymphocytes or leukocytes, respectively, relative to the expected age-adjusted telomere length. TERF1 autoantibodies were present in 11/152 (7.2%) patients with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disease believed to be mediated by telomere dysfunction. CONCLUSIONS: Autoantibodies targeting telomere-associated proteins in a subset of patients with SSc are associated with short lymphocyte telomere length and lung disease. The specificity of these autoantibodies for SSc and IPF suggests that telomere dysfunction may have a distinct role in the pathogenesis of SSc and pulmonary fibrosis.
引用
- Adler BL, Boin F, Wolters PJ, et al. Autoantibodies targeting telomere-associated proteins in systemic sclerosis. Ann Rheum Dis. 2021. PMID: 33495152. doi:10.1136/annrheumdis-2020-218918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。